The Efficacy of Intravenous versus Subcutaneous Recombinant Erythropoietin in Obese African-African Patients in a Southeast U.S. Dialysis Cohort

Abstract

Aims: To correct renal anemia, subcutaneous (SC) route of recombinant human erythropoietin (rhuEPO) administration has been associated with increased efficacy and decreased dose requirements, when compared with intravenous (IV) route. The effect of obesity as a potential modifier during rhuEPO administration has not been well explored. Research ArticleBritish Journal of Medicine & Medical Research, 4(1): 184-193, 2014 185 Methodology: We performed IV to SC rhuEPO conversion for 86 in-center dialysis patients and, following a six-month equilibration period, we monitored outcomes over a period of three months. We obtained baseline demographic parameters, calculated Body Mass Index (BMI) and monitored iron saturation, ferritin, hemoglobin (Hgb) along with rhuEPO requirements. Patients were divided into 3 categories based on BMI [<25 (n=27), 25-35 (n=38)

Successful Practice Transitioning Between Hemodialysis and Hemodiafiltration in Outpatient Units: Ten Key Issues for Physicians to Remember

“…This observation remains somewhat debated in the literature with some (43)(44)(45)(46) but not all (47,48) published data supporting it. While obesity may be a potential confounder, as well as the route of administration (IV vs. SC) (49), we observed that European subjects receiving HDF needed roughly the same dose of EPO for an entire month as HD patients in the United States did in a week under similar treatment times (50). To what degree this phenomenon is due to different water preparation quality standards vs. the utilization of convective clearance incorporated into dialysis sessions, is insufficiently explored at present time (45,51,52).…”